Autoantibody Reduction Therapy for Idiopathic Pulmonary Fibrosis

(STRIVE II Trial)

This trial tests a new combination treatment for idiopathic pulmonary fibrosis (IPF), a lung disease that makes breathing difficult. The treatment combines three components: therapeutic plasma exchange (a blood filtering process), rituximab (a medication targeting certain immune cells), and intravenous immunoglobulin (a therapy using antibodies). The goal is to determine if this combination can slow lung damage more effectively than standard treatments. Individuals who have had IPF for less than ten years and have experienced worsening symptoms might be suitable for this study. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to potentially groundbreaking advancements in IPF treatment.

Research has shown that intravenous immunoglobulin (IVIg) is usually well-tolerated, though some studies mention risks like lung injury related to transfusions. Studies indicate that rituximab can help maintain or improve lung function in some patients, but there is a risk of serious infections or reactions during infusion, such as breathing problems. Therapeutic plasma exchange (TPE) is considered safe when performed by experienced professionals, although low blood pressure commonly occurs as a side effect. Each treatment carries different risks, so prospective participants should consider these when deciding to join a trial.¹²³⁴⁵

Unlike the standard treatments for idiopathic pulmonary fibrosis, which generally focus on managing symptoms with medications like pirfenidone and nintedanib, Autoantibody Reduction Therapy (AART) offers a fresh approach. This treatment works by reducing harmful autoantibodies through a combination of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin (IVIg). Researchers are excited about AART because it directly targets the immune system's faulty response, potentially slowing disease progression more effectively than current options. Additionally, the combination of plasma exchange and immunotherapy might provide a more comprehensive attack on the underlying causes of the disease, offering hope for improved outcomes.

Research has shown that combining different treatments in Autoantibody Reduction Therapy (AART), which participants in this trial may receive, may benefit people with idiopathic pulmonary fibrosis (IPF). Rituximab, one of these treatments, improved lung function by 6.7% in some patients. Another treatment in the AART arm, therapeutic plasma exchange, has been linked to better survival rates; one study showed a 70% survival rate compared to 20% in past cases. While intravenous immunoglobulin (IVIg) is commonly used for immune-related issues, its exact role in treating IPF remains unclear, though it supports the immune system. Overall, these treatments aim to reduce harmful proteins called autoantibodies that attack the body's own tissues, potentially slowing the progression of IPF.⁶⁷⁸⁹¹⁰